MaxCyte Stock – Investing in the Future of Cell Therapy
Sometimes our new subscribers will ask for “stock picks,” and we’re quick to explain that’s not how we operate. We manage our own portfolio of tech stocks based on our unique needs and risk profile. Our subscribers, many of whom are professional money managers, derive insights from our research since we document every investment decision we make. Our goal is to complement their investment decisions, not dictate them. In the end, we want to help all our subscribers become better investors.
One benefit of not pretending like we’re market oracles is that our subscribers will engage us with their own thoughts and strategies. One lad from the land down under recently asked us for leniency on our $1 billion market cap cutoff rule citing companies like CELLINK and Tobii as two names we would have done well to invest in sooner rather than later. Survivorship bias aside, if you make one exception, what’s to keep you from making more? That’s a rule we’ll be sticking to, but that doesn’t keep us from writing about smaller companies. Today, we’re going to look at a life sciences stock brought to our attention by one of our subscribers that recently passed the $1 billion market cap threshold.
